Johannes Levin

Has grant

Professor for Clinical Neurodegeneration

Ludwig-Maximilians-Universität München

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Johannes Levin is a Professor for Clinical Neurodegeneration at Ludwig-Maximilians-Universität München, Germany. His research areas include neurodegenerative diseases, with a focus on conditions such as frontotemporal dementia, Parkinson's disease, and Alzheimer's disease, as evidenced by his recent publications. His work encompasses neuroimaging, proteomic analysis, and the development of assessment scales for clinical applications.

Recent Grants

Grant: Close

MSCoreSys-Forschungskern: CLINSPECT-M - Klinisches Massenspektrometrie Zentrum München, Teilprojekt B

Open Date: 2020-03-01

Close Date: 2023-02-28

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (26)

Nico Scherf

Max Planck Institute for Human Cognitive and Brain Sciences

GERMANY

Johannes Levin

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (30)

Criminal Behavior in Frontotemporal Dementia: A Multimodal MRI Study

Associations between neuropsychological profile and regional brain FDG uptake in progressive supranuclear palsy

A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson's disease.

Extended Technical and Clinical Validation of Deep Learning-Based Brainstem Segmentation for Application in Neurodegenerative Diseases.

Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.

Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.

The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset.

A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy.

Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases.

Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.

Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome

Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors

Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [<sup>18</sup>F]PI-2620

Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies

α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden

Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia.

Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results.

Assessment of [<SUP>18</SUP>F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function

Association of Neurofilament Light Chain, [<SUP>18</SUP>F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid-Negative CBS

Associations between sex, body mass index and the individual microglial response in Alzheimer's disease

Brain MRI in Progressive Supranuclear Palsy with Richardson's Syndrome and Variant Phenotypes

Temporal order of clinical and biomarker changes in familial frontotemporal dementia

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes

Additive value of [<sup>18</sup>F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.

The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations.

Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study.

Corrigendum to "Dissemination in time and space in presymptomatic granulin mutation carriers: A spatial chronnectome study" [Neurobiology of Aging Volume 108, December 2021, Pages 155-167].

Exploring Links Between Psychosis and Frontotemporal Dementia Using Multimodal Machine Learning: Dementia Praecox Revisited.

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia.

Collaborators (26)

Nico Scherf

Arabella Bouzigues

John C Morris

Matthias Schroeter

Stephen Wood

Ruth Mark

Joel Simrén

Dorothee Saur

Martina Bocchetta

Kazushi Suzuki

John Morris

Sami Barmada

Andre Strydom

Markus Otto

Rick van Minkelen

Karsten Mueller

Claudia Lenz

Charlene Supnet

Carolina Maruta

Amy Wise

Frederico Simões do Couto

Cyril Pottier

Thilo van Eimeren

Andrea Bozoki

Asaad Baksh

Nelly Joseph-Mathurin

Make your next move.